Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-03-17
2004-03-30
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S350000, C514S561000
Reexamination Certificate
active
06713497
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to methods for treating mammals having excess gamma amino butyric acid (GABA) in the central nervous system (CNS). The invention is especially aimed at mammals having visual field defects as a result of excess GABA.
Certain drugs are known to increase GABA levels in the brain (i.e. GABAergic drugs). These drugs are well known to be effective in the treatment of conditions such as seizure disorders.
Recently, it has been discovered that some GABAergic drugs, for example, gamma vinyl GABA (GVG), are also effective for treating and preventing drug addiction. See U.S. Pat. Nos. 6,057,368 and 6,395,783 to Dewey et al., and pending U.S. patent application Ser. Nos. 09/189,166, 09/209,952, 09/362,592, and 09/853,548.
However, there are undesirable side effects, including visual disturbances, associated with the use of GABAergic drugs. In particular, there have been reports of visual field defects (VFDs) associated with the use of GVG. Although the mechanism responsible for GVG-induced VFDs is unknown, it is believed that GVG's visual toxicity may be related to a significant elevation of GABA levels within the retina. See Comaish, IF et al., “The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.” Doc Opthalmol 104:195-212(2002);
It is known that GVG irreversibly inhibits the GABA-degrading enzyme GABA transaminase (GABA-T) and thereby induces an increase in brain GABA levels. It has also been shown that GVG-induced increases in GABA cause a decrease in glutamate decarboxylase (GAD), which is another GABA synthesizing enzyme.
To date, there have been no proposed strategies for treating or preventing the VFDs associated with the use of GABAegic drugs such as GVG. Therefore, there exists a need for a treatment for VFDs associated with the use of GABAergic drugs, such as GVG.
It is thus an object of the present invention to provide a composition and method for treating and/or preventing VFDs associated with the use of GABAergic drugs such as GVG.
SUMMARY OF THE INVENTION
The invention provides a method for treating visual field defects in a mammal in need thereof. The method includes administering an effective amount of vitamin B6 to the mammal.
According to the invention, the mammal is preferably a human. The vitamin B6 is administered in an amount from approximately 5 to 300 mg/day, preferably approximately 50 to 100 mg/day and more preferably approximately 10 to 50 mg/day.
In one embodiment of the invention, the mammal is being treated with gamma vinyl GABA for a drug addiction. In another embodiment, the mammal is being treated with gamma vinyl GABA for a seizure disorder.
In accordance with the invention, the vitamin B6 is administered before, simultaneously, or after administration of a GABAergic drug.
The invention also provides novel compositions which include a GABAergic drug and vitamin B6, preferably in a pharmaceutically acceptable carrier. In a preferred embodiment, the GABAergic drug is gamma vinyl GABA.
As a result of the present invention, a method is provided for treating visual field defects associated with excess GABA levels in the central nervous system of a mammal.
REFERENCES:
patent: 4002758 (1977-01-01), Bigou
patent: 4540582 (1985-09-01), Seiler et al.
patent: 4595697 (1986-06-01), Seiler et al.
patent: 4973467 (1990-11-01), Sahley
patent: 4980168 (1990-12-01), Sahley
patent: 5051258 (1991-09-01), Sahley
patent: 5189064 (1993-02-01), Blum et al.
patent: 5385939 (1995-01-01), Laties et al.
patent: 5567731 (1996-10-01), Laties et al.
patent: 5681578 (1997-10-01), Sahley
patent: 6057368 (2000-05-01), Dewey et al.
patent: 2002/0048612 (2002-04-01), Evans et al.
Gardner et al., Synapse, 46(4), pp. 240-250 (Dec. 15, 2002) (abstract).*
Nabbout, R., Drug Safety, 24/11, pp. 813-28 (2001 (abstract).*
S. G. Mueller, O. M. Weber, P. Boesiger and H. G. Wieser, “Influence of pyridoxal 5′-phosphate alone and in combination with vigabatrin on brain GABA measured by 1H-NMR-spectroscopy”,Brain Research Bulletin, vol. 55, No. 4, pp. 555-590 (2001).
Bogosian Margaret C.
Brookhaven Science Associates LLC
Spivack Phyllis G.
LandOfFree
Use of vitamin B6 to mitigate visual field defects... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of vitamin B6 to mitigate visual field defects..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of vitamin B6 to mitigate visual field defects... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3269552